Authored By: Sarah
11 Jul 2024

 Atherosclerosis Therapeutics Market Size to grow by USD 2660.1 million between 2024-2028

According to a research report “ Atherosclerosis Therapeutics Market” by Product (Small molecules, Biologics) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 2660.1 million, at a CAGR of  4.5% during the forecast period. Atherosclerosis is a complex, multifactorial disease characterized by the progressive narrowing and hardening of arterial walls. Obesity is a significant risk factor for atherosclerosis, with the association being mediated through various abnormalities, including hypertension, diabetes, and lipoprotein abnormalities. These comorbidities are known to increase the risk of atherosclerosis development and progression. A comprehensive understanding of the risk factors for atherosclerosis requires a clear linkage to the disease, with obesity's influence being consistently supported by the scientific evidence.

Browse market data tables, figures, and in-depth TOC on “Atherosclerosis Therapeutics Market” by Product (Small molecules, Biologics) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Product, the Small molecules segment is projected to dominate the market size in 2024

ai_market_segmentation_by

By Geography, North America  segment is expected to hold the largest market size for the year 2024

The Atherosclerosis Therapeutics Market represents a significant business opportunity due to the rising prevalence of cardiovascular diseases and the increasing demand for effective treatments. Key players in this market are developing innovative therapies to address the root causes of atherosclerosis, such as inflammation and plaque formation. These advancements are expected to drive market growth, making it an attractive investment for businesses in the healthcare sector.

North America is forecasted to hold the largest market size by region in 2024

The Atherosclerosis Therapeutics Market represents a significant business opportunity due to the rising prevalence of cardiovascular diseases and the increasing demand for effective treatments. Key players in this market are developing innovative therapies to address the root causes of atherosclerosis, such as inflammation and plaque formation. These advancements are expected to drive market growth and provide substantial returns for investors. Strategic collaborations and partnerships are also crucial for companies to stay competitive in this dynamic industry.

The Atherosclerosis Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Amgen Inc.
  • AstraZeneca Plc
  • Dr Reddys Laboratories Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Ionis Pharmaceuticals Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Viatris Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Atherosclerosis, a chronic vascular illness characterized by the buildup of plaque made up of cholesterol, fatty materials, calcium, and cellular waste products in the arteries, is a significant global health concern. The atherosclerosis drugs market is witnessing growth due to the increasing prevalence of this condition, driven by factors such as an unhealthy lifestyle, aging population, and comorbidities like diabetes and hypertension. Statin treatment is a common therapy for managing atherosclerosis by reducing cholesterol levels. However, statins can trigger an inflammatory response and cytokine storm, which may worsen vasomotor tone and endothelial cell dysfunction. SARS CoV2 infection can also exacerbate chronic endothelial inflammation, leading to complications in the lungs and other extremities. Clinical trials are ongoing for new therapies targeting the inflammatory response and hemostatic balance in atherosclerosis. ACE inhibitor medications, beta blocker medications, cholesterol-lowering medications, and antiplatelet medications are among the current treatments for managing atherosclerosis in various body organs. The market for atherosclerosis drugs is expected to grow as health-conscious consumers seek effective therapies to prevent and manage this chronic condition. The inflammatory response and hemostatic imbalance in atherosclerosis are key targets for new drug development, with a focus on modulating fibrin and other components of plaque formation.

Market Research Overview

Atherosclerosis, a chronic inflammatory condition characterized by the buildup of plaque in the arteries, is a leading cause of cardiovascular diseases (CVDs), including ischemic heart disease, artery blockages, myocardial infarction, arterial thrombosis, stroke, and ischemia. Factors contributing to its prevalence include energy dense foods, sedentary lifestyles, high alcohol consumption, obesity, high cholesterol, and high blood pressure. The atherosclerosis drugs market includes various therapeutics such as fibrates, statins, and cytokine storm modulators. Statins, the most commonly prescribed drugs, inhibit the production of cholesterol in the liver. Fibrates, on the other hand, help the body use fat more effectively and increase the production of good cholesterol. Diagnostic rates for atherosclerosis are increasing due to the infrastructure development of healthcare services and the availability of generic products. The market also includes injectable and oral medications, administered through drug stores, online providers, hospital pharmacies, and clinical trials. The prevalence of atherosclerosis is particularly high in the geriatric population and those with unhealthy lifestyles and poor eating habits, such as high consumption of carbohydrate-based foods. Thrombotic problems, inflammation, and chronic endothelial inflammation are key drivers of atherosclerosis, and treatments aim to restore vasomotor tone and hemostatic balance. The SARS CoV2 infection has also been linked to atherosclerosis, with potential mechanisms including inflammation and endothelial damage in the lungs and other body organs. The atherosclerosis drugs market is expected to grow due to the increasing prevalence of atherosclerosis and the development of new treatments, such as polymer-based therapies for plaque removal and antiplatelet medications for preventing clot formation.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio